Looking for the Best Immune-Checkpoint Inhibitor in Pre-Treated NSCLC Patients: An Indirect Comparison Between Nivolumab, Pembrolizumab and Atezolizumab

International Journal of Cancer - United States
doi 10.1002/ijc.31136
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

P3.04-14 TMB and Immune Checkpoint Inhibitor Gene Expression Are Unrelated in NSCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Pcn38 - Nivolumab Is Predicted to Have Improved Clinical Outcomes Over Best Supportive Care in a Western Population of Pre-Treated Gastric Cancer Patients; An Indirect Treatment Comparison Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

P1.01-07 Immune-Related Pneumonitis in NSCLC Patients Treated With Immune Checkpoint Inhibitors (ICI): Impact of Previous Thoracic Radiotherapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Correction: Nods for Atezolizumab and Nivolumab From FDA

Cancer Discovery
Oncology
2017English

Delayed Immune-Related Erythrodermia in a Squamous NSCLC Patient Treated With Nivolumab: A Case Report

Journal of Cancer Research and Immuno-Oncology
2018English

MA08.09 Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Workup and Management of Immune‐Mediated Colitis in Patients Treated With Immune Checkpoint Inhibitors

Oncologist
Cancer ResearchMedicineOncology
2019English

Can an Immune Checkpoint Inhibitor (Sometimes) Make Things Worse?

Clinical Cancer Research
Cancer ResearchOncology
2017English

Association Between EKG Alterations and Clinical Outcomes in Immune Checkpoint Inhibitor-Associated Myocarditis

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy